Citations

Showing 10 of 108119 citations.

Treatment of Women After Bilateral Salpingo-oophorectomy Performed Prior to Natural Menopause
Kaunitz, Andrew M., Kapoor, Ekta , Faubion, Stephanie, Faubion, Stephanie S.

Mayo Clinic

JAMA | October 13, 2021 | Volume: 326 | Issue: 14 | Pages: 1429

10.1001/jama.2021.3305 | PMID 34636868 Get It

Faculty Opinions recommendation of Engineered nasal cartilage for the repair of osteoarthritic knee cartilage defects.
Evans, Christopher H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 13, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.740734893.793588593 Get It

Diversity Matters: A 21-Year Review of Trends in Resident Recruitment into Surgical Specialties
Mohan, Anita T. , Banuelos, Joseph, Cespedes-Gomez, Omar, Kapoor, Trishul , Moran, Steven L. , Heller, Stephanie F. , Dozois, Eric J. , Nelson, Heidi, Stulak, John M., Martinez‐Jorge, Jorys

Mayo Clinic

Annals of Surgery Open | October 13, 2021 | Volume: 2 | Issue: 4 | Pages: e100

10.1097/as9.0000000000000100 | PMID 37637873 Get It

Background: Diversity within the healthcare workforce is essential to improve quality of care, although evaluation of diversity within surgical training remains limited. This study analyzed diversity in recruitment of residents into surgical subspecialties at a large academic medical institution and national trends. Methods: A 21-year cross-sectional study of medical school graduates accepted into all surgical subspecialty training programs was performed. The institutional cohort was divided into two groups (1997–2006, 2007–2017). Subspecialty acceptance rates were determined between 2011 and 2018. Data on candidate demographics including gender, race, ethnicity, citizenship, and origin of medical education at a single institution and nationally were extracted. Results: Two thousand found hundred seventy-two residents were included in this study. From 1997 to 2018, female acceptances increased from 21.1% to 29.7% (p < 0.01), non-White increased from 27.9% to 31.8% (p = 0.01), and international medical graduates decreased from 28.8% to 25.5% (p = 0.02). There was no significant change in accepted Hispanic and Non-US candidates. Female subspecialty rates for subspecialties increased nationally and was comparable to our cohort, except in general surgery. Hispanic subspecialty acceptance rates were less than 10% and Black/African American acceptance rates remained less than 5% across subspecialties nationally and at our institution. Conclusion: Diversity in surgical training has modestly progressed over the last two decades, but the degree of positive change has not been universal and highlights the critical need for improvement and action. Continued institution driven and collaborative strategies are essential to promote diversity in recruitment across all surgical specialties that has implications on our future workforce and surgical leadership.
FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs
O’Shaughnessy, Elizabeth, Yasinskaya, Yuliya, Dixon, Cheryl, Higgins, Karen , Reynolds, Kellie, Ampel, Neil M. , Angulo, David, Blair, Janis E. , Catanzaro, Antonino , Galgiani, John N. , Garvey, Edward P., Johnson, Royce H. , Larwood, David J. , Purdie, Rob , Stevens, David A. , Shukla, Sunita J. , Farley, John, Nambiar, Sumathi , Higgins, Karen, Moore, Jason, Reynolds, Kellie, Lewis, Gareth A. , Rex, John H. , Shubitz, Lisa F. , Page, Stephen John

Mayo Clinic

Clinical Infectious Diseases | October 13, 2021 | Volume: 74 | Issue: 11 | Pages: 2061-2066

10.1093/cid/ciab904 | PMID 34651656 Get It

Abstract Coccidioidomycosis is a fungal disease endemic to the southwestern United States, Mexico, and Central and South America. Prevalence rates are increasing steadily, and new endemic areas of Coccidioides are emerging. Standard treatment is often administered for months to decades, and intolerance to medications and treatment failures are common. No new treatments for coccidioidomycosis have been approved in the United States in nearly 40 years. On 5 August 2020, the US Food and Drug Administration convened experts in coccidioidomycosis from academia, industry, patient groups, and other government agencies to discuss the disease landscape and strategies to facilitate product development for treatment of coccidioidomycosis. This article summarizes the key topics concerning drug development for coccidioidomycosis presented by speakers and panelists during the workshop, such as unmet need, trial designs, endpoints, incentives, research and development support, and collaborations to facilitate antifungal drug development.
Adult liver transplant anesthesiology practice patterns and resource utilization in the United States: Survey results from the society for the advancement of transplant anesthesia
Crouch, Cara , Sakai, Tetsuro , Aniskevich, Stephen , Damian, Daniela , Marchi, Lorenzo De , Kaufman, Michael D. , Kumar, Sathish S. , Little, Michael, McCluskey, Stuart A. , Pivalizza, Evan G. , Sellers, Daniel , Sridhar, Srikanth , Stoll, W , Sullivan, Cinnamon, Hendrickse, Adrian , Stoll, William , Aniskevich, Stephen

Mayo Clinic

Clinical Transplantation | October 13, 2021 | Volume: 36 | Issue: 1 | Pages: No page available

10.1111/ctr.14504 | PMID 34637561 Get It

AbstractIntroductionLiver transplant anesthesiology is an evolving and expanding subspecialty, and programs have, in the past, exhibited significant variations of practice at transplant centers across the United States. In order to explore current practice patterns, the Quality & Standards Committee from the Society for the Advancement of Transplant Anesthesia (SATA) undertook a survey of liver transplant anesthesiology program directors.MethodsProgram directors were invited to participate in an online questionnaire. A total of 110 program directors were identified from the 2018 Scientific Registry of Transplant Recipients (SRTR) database. Replies were received from 65 programs (response rate of 59%).ResultsOur results indicate an increase in transplant anesthesia fellowship training and advanced training in transesophageal echocardiography (TEE). We also find that the use of intraoperative TEE and viscoelastic testing is more common. However, there has been a reduction in the use of veno‐venous bypass, routine placement of pulmonary artery catheters and the intraoperative use of anti‐fibrinolytics when compared to prior surveys.ConclusionThe results show considerable heterogeneity in practice patterns across the country that continues to evolve. However, there appears to be a movement towards the adoption of specific structural and clinical practices.
Application of Human Adipose-Derived Stem cells for Bone Regeneration of the Skull in Humans
Torres‐Guzman, Ricardo A. , Huayllani, María T. , Maita, Karla C. , Quiñones‐Hinojosa, Alfredo , Forte, Antonio J. , Forte, Antonio Jorge , Torres, Ricardo A , Ávila, Francisco R. , Zubair, Abba C. , Sarabia-Estrada, Rachel

Mayo Clinic

Journal of Craniofacial Surgery | October 13, 2021 | Volume: 33 | Issue: 1 | Pages: 360-363

10.1097/scs.0000000000008114 | PMID 34636755 Get It

Background: Archeological archives report cranioplasty as 1 of the oldest surgical procedures; however, it was not until the last century that true advances have been made. Alternative approaches are necessary to achieve optimal closure of the defect with fewer adverse effects. We aim to evaluate the use of human adipose-derived stem cells (hADSCs) alone or seeded in scaffolds as the main treatment for cranial bone defects and to assess human patient outcomes. Methods: A systematic review was performed by querying PubMed, Ovid MEDLINE, EMBASE, and Cumulative Index to Nursing and Allied Health Literature databases with the MeSH terms: “adipose-derived stem cells,” “cranial bone defect,” “stromal vascular factor,” “fat grafting,” as well as synonyms in combinations determined by our search strategy. We included human models that used hADSCs as primary therapy. We excluded studies in languages other than English. Results: One hundred ninety-four studies were identified after removal of duplicates. Four articles that used hADSCs as the main therapy to treat calvarial defects in humans were included. One article applied the cell therapy alone, and 3 used β-tricalcium phosphate granules as a scaffold to seed the hADSCs. Conclusions: Bone regeneration was reached in a short and intermediate period using autologous hADSCs in humans with no major adverse effects in all 4 articles included. A long-term follow-up study (6 years) exhibited late infections and reabsorption of the β-tricalcium phosphate scaffold seeded with hADSCs.
Application and Clinical Value of Definitive Drug Monitoring in Pain Management and Addiction Medicine
Rosano, T G , Wood, Michelle , Hooten, W. Michael , Rumberger, John M., Argoff, Charles E. , Rosano, Thomas G , Fudin, Jeffrey

Mayo Clinic

Pain Medicine | October 13, 2021 | Volume: 23 | Issue: 4 | Pages: 821-833

10.1093/pm/pnab303 | PMID 34643732 Get It

Abstract Objective To assess routine application and clinical value of definitive urine drug monitoring (UDM) for drug detection, inconsistent drug use, and prescription adherence, along with a comparison to immunoassay screening (IAS). Methods Direct-to-definitive UDM performance was analyzed retrospectively in 5000 patient specimens. Drug findings, medication inconsistencies, and detection sensitivity were assessed, and definitive UDM versus IAS monitoring was studied. Results Definitive testing resulted in 18,793 drug findings with 28,403 positive drug and metabolite tests. Definitive testing expanded monitoring with 11,396 drug findings that would not be tested by IAS. The opioids accounted for the highest frequency of inconsistent positive drug-use findings, at 12%. Conversely, inconsistent negative drug findings, used as an index of prescription non-adherence, were determined in 1,751 of 15,409 monitored medications and included a high frequency of antidepressants and antipsychotics inconsistencies. Direct comparison of definitive UDM and IAS showed false-positives by IAS as well as a high rate of false-negatives that would be missed using current confirmation protocols. Conclusions Results from routine application of direct-to-definitive UDM demonstrate the clinical value of drug-use identification and the objective evaluation of inconsistencies in drug misuse and medication adherence in pain management and addiction medicine practice. Without conversion to direct-to-definitive UDM, continuing use of IAS will limit the scope of drugs being tested, will result in an indeterminate rate of false negatives and will require confirmation testing to eliminate the reporting of false-positive IAS tests. The findings in this study provide evidence-based support for recommended use of a direct-to-definitive drug testing protocol.
Role of blue‐light cystoscopy in detecting invasive bladder tumours: data from a multi‐institutional registry
Ahmadi, Hamed , Ladi‐Seyedian, Seyedeh‐Sanam , Konety, Badrinath R. , Pohar, Kamal S. , Holzbeierlein, Jeffrey M., Kates, Max , Willard, Brian, Taylor, Jennifer M. , Kaimakliotis, Hristos Z. , Porten, Sima P. , Tyson, Mark D. , Group, the Blue Light Cystoscopy with Cysview Registry, Lotan, Yair , Daneshmand, Siamak , Liao, Joseph C. , Steinberg, Gary D. , Lotan, Yair , Daneshmand, Siamak , Group, the Blue Light Cystoscopy with Cysview Registry

Mayo Clinic

BJU International | October 13, 2021 | Volume: 130 | Issue: 1 | Pages: 62-67

10.1111/bju.15614 | PMID 34637596 Get It

Objectives To evaluate the role of blue‐light cystoscopy (BLC) in detecting invasive tumours that were not visible on white‐light cystoscopy (WLC). Patients and Methods Using the multi‐institutional Cysview registry database, patients who had at least one white‐light negative (WL–)/blue‐light positive (BL+) lesion with invasive pathology (≥T1) as highest stage tumour were identified. All WL–/BL+ lesions and all invasive tumours in the database were used as denominators. Relevant baseline and outcome data were collected. Results Of the 3514 lesions (1257 unique patients), 818 (23.2%) lesions were WL−/BL+, of those, 55 (7%) lesions were invasive (48 T1, seven T2; 47 unique patients) including 28/55 (51%) de novo invasive lesions (26 unique patients). In all, 21/47 (45%) patients had WL−/BL+ concommitant carcinoma in situ and/or another T1 lesions. Of 22 patients with a WL−/BL+ lesion who underwent radical cystectomy (RC), high‐risk pathological features leading to RC was only visible on BLC in 18 (82%) patients. At time of RC, 11/22 (50%) patients had pathological upstaging including four (18%) with node‐positive disease. Conclusions A considerable proportion of invasive lesions are only detectable by BLC and the rate of pathological upstaging is significant. Our present findings suggest an additional benefit of BLC in the detection of invasive bladder tumours that has implications for treatment approach.
EBV+ high‐grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi‐institutional study
Liu, Hui , Wang, Wei , Kim, Young , Ji, Yuan , Chen, Weina , Fedoriw, George Y, Zhu, Feng , Luedke, Catherine, Hu, Shimin , Hu, Shimin , Yuan, Ji , Xu‐Monette, Zijun Y. , Tang, Guilin , Li, Yu , Li, Yanping , Fang, Xiaosheng , Medeiros, L. Jeffrey , Young, Ken H.

Mayo Clinic

Histopathology | October 13, 2021 | Volume: 80 | Issue: 3 | Pages: 575-588

10.1111/his.14585 | PMID 34637146 Get It

AimsIt is unknown whether Epstein–Barr virus (EBV) infection can occur in high‐grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double‐ or triple‐hit lymphoma (DHL/THL).Methods and resultsHere we report 16 cases of EBV+ DHL/THL from screening 846 cases of DHL/THL and obtaining additional EBV+ cases through multi‐institutional collaboration: eight MYC and BCL2 DHL, six MYC and BCL6 DHL and two THL. There were eight men and eight women, with a median age of 65 years (range = 32–86). Two patients had a history of follicular lymphoma and one had AIDS. Nine of 14 patients had an International Prognostic Index of ≥3. Half of the cases showed high‐grade/Burkitt‐like morphology and the other half diffuse large B cell lymphoma morphology. Using immunohistochemistry, the lymphoma cells were positive for MYC (n = 14 of 16), BCL2 (n = 12 of 16), BCL6 (n = 14 of 16), CD10 (n = 13 of 16) and MUM1 (n = six of 14). Using Hans’ algorithm, 13 cases were classified as germinal centre B cell (GCB) and three as non‐GCB. The lymphomas frequently showed an EBV latency Type I with a median EBV‐encoded small RNAs of 80% positive cells (range = 20–100%). After a median follow‐up of 36.3 months (range = 2.0–41.6), seven patients died, with a median survival of 15.4 months (range = 3.4–47.3) after diagnosis of EBV+ DHL/THL. Five of six patients with MYC and BCL6 DHL were alive, including four in complete remission. In contrast, only four of 10 patients with MYC and BCL2 DHL or THL were alive, including two in complete remission. The median survival in patients with MYC and BCL6 DHL was unreached and was 21.6 months in patients with MYC and BCL2 DHL or THL.ConclusionsEBV infection in DHL/THL is rare (~1.5%). Cases of EBV+ DHL/THL are largely similar to their EBV– counterparts clinicopathologically. Our findings expand the spectrum of EBV+ B cell lymphomas currently recognised in the World Health Organisation classification and suggest differences between EBV+ MYC and BCL2 DHL versus EBV+MYC and BCL6 DHL that may have therapeutic implications.